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Persistent inequalities in 90-day colon cancer
mortality: an English cohort study
H Fowler*,1, A Belot1, E N Njagi1, M A Luque-Fernandez1, C Maringe1, M Quaresma1, M Kajiwara1 and
B Rachet1
1Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population
Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
Background: Variation in colon cancer mortality occurring shortly after diagnosis is widely reported between socio-economic
status (SES) groups: we investigated the role of different prognostic factors in explaining variation in 90-day mortality.
Methods: National cancer registry data were linked with national clinical audit data and Hospital Episode Statistics records for
69 769 adults diagnosed with colon cancer in England between January 2010 and March 2013. By gender, logistic regression was
used to estimate the effects of SES, age and stage at diagnosis, comorbidity and surgical treatment on probability of death within
90 days from diagnosis. Multiple imputations accounted for missing stage. We predicted conditional probabilities by prognostic
factor patterns and estimated the effect of SES (deprivation) from the difference between deprivation-specific average predicted
probabilities.
Results: Ninety-day probability of death rose with increasing deprivation, even after accounting for the main prognostic factors.
When setting the deprivation level to the least deprived group for all patients and keeping all other prognostic factors as
observed, the differences between deprivation-specific averaged predicted probabilities of death were greatly reduced but
persisted. Additional analysis suggested stage and treatment as potential contributors towards some of these inequalities.
Conclusions: Further examination of delayed diagnosis, access to treatment and post-operative care by deprivation group may
provide additional insights into understanding deprivation disparities in mortality.
Colon cancer, the fourth most frequently diagnosed cancer in
England, has a less favourable 1-year prognosis in England when
compared with some other common cancers, such as cancers of the
rectum and breast (Exarchakou et al, 2015). One-year net survival
for colon cancer (i.e., the survival of colon cancer if the other
causes of death have been removed) was recently reported at
around 75%, while it was largely 480% for the other cancers
mentioned above (Exarchakou et al, 2015). Meanwhile, wide socio-
economic inequalities in survival from colon cancer have been
repeatedly reported in England (Mitry et al, 2008; Rachet et al,
2010), with worse prognosis for more deprived patients. These
inequalities are generally evident shortly after diagnosis (Møller
et al, 2012), with two-thirds of cancer deaths related to these
inequalities occurring within 6 months after diagnosis (Ellis et al,
2012). Socio-economic inequalities in colon cancer survival have
been reported in several countries (Wrigley et al, 2002; Aarts et al,
2010; Cavalli-Bjorkman et al, 2011; Ito et al, 2014) but have not
been found in others (Dejardin et al, 2013; Antunes et al, 2016),
which underlines the importance of understanding factors
contributing to inequalities and more particularly differential
short-term mortality in colon cancer patients in England.
Many published studies have focussed their attention exclusively
towards subgroups of colon cancer patients, such as postoperative
patients (Morris et al, 2011) or elderly postoperative patients
(Dekker et al, 2011), to explain differences in short-term survival.
A variety of indicators has been considered in studies examining
SES – from metrics such as patient occupation or education level to
deprivation indices. Common themes in the literature include
examining the relationship between age, stage at diagnosis and
short-term mortality (Gatta et al, 1998; Møller et al, 2012) and the
relationship between cancer treatment and short-term mortality
(Faivre et al, 2007). However, there was little discussion offered
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regarding the relationship between socio-economic status and risk
factors for short-term mortality, such as comorbidity or stage at
diagnosis. Awareness of factors contributing to different prognoses
for short-term survival across all patient populations is central to
the effective management of cancer care.
This study aims to quantify differences in 90-day mortality
following diagnosis of colon cancer according to patients’ socio-
economic status. We investigate to what extent these differences
are influenced by age, stage at diagnosis, patient comorbidity score,
whether the primary treatment received by the patient was a major
surgery and whether the patient received major surgery as an
elective or emergency procedure.
MATERIALS AND METHODS
Data. The analysis was undertaken on 69 769 adults aged 15–99
years diagnosed with colon cancer in England between 1 January
2010 and 31 March 2013 and followed up until 31 December 2014.
The data for these analyses were obtained from the national cancer
registry records (Office for National Statistics, 2014) linked with
Hospital Episode Statistics (HES) records (Health and Social Care
Information Centre, 2013) and national bowel cancer clinical audit
data (Health and Social Care Information Centre, 2014a) –
representing information collated from clinicians working in
multidisciplinary teams who have direct involvement with the
patients. The linkage of the registry data with clinical audit data
and HES records was undertaken using an algorithm developed by
the Cancer Survival Group at the London School of Hygiene and
Tropical Medicine (Shack, 2009), which prioritised linkage of
records according to the combination of patient identifier variables
(Office for National Statistics, 2014). The cancer registry data
represented 499% of cancer registrations in England (Office for
National Statistics, 2014) and provided information on gender, age
at diagnosis, socio-economic status, tumour stage and date of
diagnosis. The clinical audit data had a case ascertainment of 94%
(Health and Social Care Information Centre, 2014b) and captured
information on tumour stage and treatment. To obtain the most
robust information on stage at diagnosis from clinical audit and
registry data, we used an algorithm (Benitez-Majano et al, 2016)
that creates a composite stage at diagnosis variable, based on the
rules of the Union for International Cancer Control TNM
classification of malignant tumours. It combined available
information in individual tumour (T), nodes (N) and metastases
(M) stage components, prioritising information captured in the
clinical audit data and only using registry stage data where this was
not present, to derive a four-level ordinal stage variable, where
stage 1 represents localised stage cancer and stage 4 indicates
metastatic stage cancer (Benitez-Majano et al, 2016).
HES records were used to supplement treatment information
gathered from the clinical audit data and to derive information on
comorbidity prevalence. We devised an algorithm to derive the first
major surgical treatment received by each patient within a time
window of between 30 days prior and 90 days following cancer
diagnosis. Treatment information was derived from data coded
according to the Office of Population Censuses and Surveys
(OPCS) Classification of Interventions and Procedures (fourth
version, ‘OPCS-4’) (Health and Social Care Information Centre,
2017). The OPCS-4 codes represent an information standard used
by clinical coders within National Health Service hospitals in Great
Britain. In the clinical audit data, we used the sole OPCS-4-coded
treatment variable describing the patient’s primary procedure. In
HES up to 12 fields (among a total of 20) capturing OPCS-4-coded
treatment information had been completed for each hospital
episode. Major surgery was categorised using the definition of
major treatment devised by the Site-Specific Clinical Reference
Groups of the National Cancer Intelligence Network (National
Cancer Intelligence Network, 2013), which sought extensive input
from clinicians and oncologists. Supplementary Table 1 defines
OPCS-4 codes representing major surgery for colon cancer.
Surgery presentation was defined as either ‘emergency’ or ‘elective’,
according to the method of admission recorded in HES.
Information on the presence of comorbidities and other
conditions were derived from the historical records of diagnosis
fields in HES between 2003 and 2013, allowing the capture of
information up to 6.5 years prior to cancer diagnosis. Each hospital
spell record can contain up to 20 diagnostic fields in which
coexisting conditions could be recorded. We extracted information
on the prevalence of the 17 comorbidities of the Charlson Index
(Charlson et al, 1987) plus obesity by applying an algorithm
(Maringe et al, 2017) that created a binary variable to flag the
presence of each of the comorbidities of interest prior to the date of
cancer diagnosis recorded in the registry data. We considered
comorbidities recorded during a retrospective 6-year period from
0.5 to 6.5 years prior to cancer diagnosis in the analysis. Cancer
registry data were the source of information for the two Charlson
Index comorbidities relating to cancer (i.e., ‘any malignancy’ and
‘metastatic solid tumours’). However, stage information was largely
missing for many cancers and, where available, we found only 11
colon cancer patients with a metastatic tumour (i.e., TNM stage 4
tumour) prior to the diagnosis of their colon cancer. We therefore
considered any prior cancer diagnosis as ‘any malignancy’ in the
context of the Charlson Index. Each patient’s Charlson Comor-
bidity Index score was calculated based on Charlson’s weighted
index of comorbidity (Charlson et al, 1987). A weighted score was
derived for each patient based on whether any of the comorbidities
had been diagnosed, as confirmed from the binary comorbidity
indicators. The Charlson Comorbidity Index scores were then
summarised by creating a four-category comorbidity score
variable, indicating whether the Charlson Comorbidity Index
score was 0, 1, 2 or X3.
We defined socio-economic status as deprivation, which was
measured using the Income Domain from the 2011 England
Indices of Multiple Deprivation (Department for Communities and
Local Government, 2011) defined at the Lower Super Output Area
level (mean population 1500). Patients were allocated to one of the
five deprivation categories according to their area of residence at
the time of their cancer diagnosis. This ecological, five-level ordinal
variable represents a scale of deprivation, where ‘1’ represents the
least deprived and ‘5’ represents the most deprived category of
patients, based on the quintiles of the distribution areas in England.
Analysis. All analyses were conducted using Stata 14 (StatCorp
LP, College Station, TX, USA) (StataCorp, 2015).
Information on patient characteristics was investigated using
cross tabulations to explore the distribution and completeness of
variables of interest for each gender.
The first step was to quantify the role of key variables on the
90-day mortality, which then enabled us to derive a series of
indicators with public health relevance, discussed in the next
subsection. Prior to conducting our analyses, the relationships
between the prognostic factors (age, stage at diagnosis, treatment
received and comorbidity score), our primary exposure of
interest (deprivation) and the outcome of interest (90-day
mortality) were considered. A directed acyclic graph depicting
the assumed relationships between these variables is provided in
Supplementary Figure 1.
We used multivariable logistic regression models to estimate the
associations between the probability of death occurring within 90
days of colon cancer diagnosis (our outcome of interest) and
deprivation as well as age at diagnosis, stage at diagnosis,
comorbidity score and treatment received, separately for each
gender. The possible nonlinear effect of age at diagnosis was
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modelled using a quadratic regression spline with one knot at 70
years (near the mean age of the patients, 72.2 years). Furthermore,
because the association between deprivation and 90-day mortality
might vary by stage, comorbidity and treatment, the initial multiple
logistic regression model included, in addition to the variables
mentioned above, the corresponding interactions. Similarly,
interactions between stage and age, stage and treatment, stage
and comorbidity and comorbidity and treatment were initially
considered on a priori clinical grounds. A backward elimination
method (Agresti, 2013) was then applied to select the most
parsimonious model to predict 90-day mortality. This final analysis
model was used to predict our outcome – probability of death
within 90 days of diagnosis. As a further step, to examine the
contribution stage and treatment made towards this outcome, we
performed additional analysis removing in turn from our final
analysis model, stage, treatment and both stage and treatment.
Multiple imputations accounted for 30% missing composite
stage, assuming a missing at random mechanism (Little and Rubin,
1987) – that is, that the probability of stage being missing
depended on the observed data. Given that the logistic regression
model included (i) interactions between stage and other variables
(and stage had missing information), and (ii) a nonlinear effect of
age, multiple imputation by the substantive-model compatible fully
conditional specification (SMC–FCS) method (Bartlett et al, 2015;
Bartlett and Morris, 2015) was employed to ensure compatibility
between the imputation model and the analysis model (Carpenter
and Kenward, 2013). Separately for each gender, a multinomial
logistic regression model was used to impute stage, including as
predictor variables, (i) all the variables in the analysis model
mentioned above, (ii) the vital status within 90 days, (iii) the
tumour grade (a four-level ordinal variable indicating the level of
differentiation of the tumour), and (iv) a variable representing the
Nelson–Aalen estimate (an estimator of the cumulative hazard of
death) (Falcaro et al, 2015). In this model, age was also included as
a nonlinear effect, to ensure compatibility (Carpenter and
Kenward, 2013) with the analysis model. Tumour grade was used
as an auxiliary variable in the imputation model, and as it also had
missing information (20% missing grade), a multinomial logistic
regression model was also used to impute it within the SMC–FCS
framework. It is important to mention that ordinal logistic
regression models, rather than multinomial logistic regression
models, could be employed to impute stage and grade, provided
that care is taken to test for the usually made proportional odds
assumption (Agresti, 2013; Carpenter and Kenward, 2013).
The Stata ‘smcfcs’ command (StataCorp, 2015) was used to
generate 30 imputed data sets, using the imputation model and
imputation strategy above. The initial multiple logistic regression
model was fitted to the 30 imputed data sets and Rubin’s Rules
(Little and Rubin, 1987) used to combine the analysis results. The
backward elimination model selection method was applied using
the ‘mi test’ command (StataCorp, 2015) to perform a multivariate
Wald test, dropping the most insignificant interaction term one at
a time; refitting the reduced model to the data imputed as above
and testing again for the remaining interactions, until all remaining
interactions were significant (P-valuep0.05). All interactions were
tested on the same set of imputed data: retaining the data imputed
using the most complex imputation model and testing all
subsequent reduced models on these same set of data ensures
valid estimation of all the reduced models (Carpenter and
Kenward, 2013; Bartlett and Morris, 2015).
Indicators produced. Using the final model selected for each
gender, we predicted two sets of probabilities of dying within 90
days of diagnosis. The first consisted of conditional probabilities,
that is, given specific values of the prognostic factors. This was
performed using the ‘mi estimate’ command (StataCorp, 2015).
The second set included average predicted probabilities estimated
for each deprivation group in turn; we predicted the probability of
death within 90 days of diagnosis for each patient, adjusting for
prognostic factors, and averaged these probabilities on all patients
in the subgroup (Muller and Maclehose, 2014). This meant the
probability of death was predicted for each patient in the
deprivation group – adjusting for the patient’s prognostic factor
values – and used to derive the average predicted probability of
death of all patients in that deprivation group. By way of
comparison, the average predicted probabilities were then
recalculated separately for each of the deprivation groups but
setting the level of deprivation as the least deprived group and with
all other prognostic factors remaining as observed. This gave an
estimate of the probability of death as if patients had been in the
least deprived group. The difference between those two probabil-
ities quantified the effect of deprivation. This was performed using
the ‘mimrgns’ command. In the additional analysis, we reiterated
this calculation of average predicted probabilities as if patients had
been in the least deprived group but using the final model without
stage, then without treatment and finally without both.
RESULTS
A total of 69 769 adults were diagnosed with colon cancer in
England between January 2010 and March 2013; 36 685 (52.6%) of
these adults were males. Table 1 shows the characteristics of the
patients in this study overall and for the 14.7 and 16.6% males and
females, respectively, who died within 90 days after a colon cancer
diagnosis. As deprivation increased the percentage of patients in
each deprivation group decreased in both genders (22.3 in
deprivation group 1 versus 15.2% in deprivation group 5 in males
and 21.4 versus 15.3% in females). However, by deprivation group,
the percentage of patients who died in 90 days increased with
deprivation: in the least deprived group, the percentage was 12.4 in
males and 13.3% in females; and in the most deprived group, the
percentages were 17.7 and 19.9 in males and females, respectively.
Both male and female elderly patients were highly represented,
especially the 80þ patients, in the patients who died within 90
days. Stage at diagnosis was missing for almost a third of the
patients but for 38.1% and 44.3% of males and females who died
within 90 days, respectively. Early stages (1 and 2) represented a
third of the patients with observed stage but about 13% of those
who died within 90 days. Only 74 males and 54 females diagnosed
with stage 1 died within 90 days, compared with42000 diagnosed
with the most advanced stage 4 (representing three-quarters of the
patients who did not survive). The patients with no recorded
comorbidity were about three-quarters of all patients but were two-
thirds of those who died within 90 days, illustrating an over-
representation of those with no recorded comorbidity among the
group who died within 90 days. About one-third of the patients did
not receive any major surgery, but this group with no treatment
represented over three-quarters of those who died within 90 days.
By contrast, o10% of the patients who did not survive received a
major elective surgery while they represented nearly half of all
patients. We provide the distribution of stage at diagnosis in
patients receiving a major emergency, major elective surgery or no
major surgery in Supplementary Table 2. Of the 14 810 patients with
known tumour stage who did not have a major surgery, 11.1% had a
stage 1 diagnosis, whereas 66.6% had a stage 4 diagnosis.
Supplementary Table 3 shows the distribution of patients who
underwent major surgery via either emergency or elective presenta-
tion – and those who did not have major surgery – by comorbidity
score. The majority of patients (51%) with the highest comorbidity
score of 3 did not undergo major surgery while 34% of these patients
had a major elective surgery. By contrast, 49% of patients with no
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recorded comorbidity had a major elective surgery and 33% no major
surgery.
In building the multivariable model for obtaining the predic-
tions of probability of death within 90 days, the model selection
strategy identified significant interactions in both male and female
patients, that is, the association between age and 90-day mortality
was modified by stage, comorbidity and treatment. There was also
an interaction between treatment and stage. In males only, one
additional interaction was retained between comorbidity score and
treatment.
Probability of death within 90 days of colon cancer diagnosis
Conditional probabilities by prognostic factor patterns. In both
male and female patients, the conditional (i.e., conditional to
specific values of factors) probability of death within 90 days rose
with increasing level of deprivation, whatever the age and stage at
diagnosis. To investigate this at a more granular level, the
deprivation groups were split into subgroups of patients, according
to the presence of comorbidities and the treatment they received.
Therefore, for each sex, probability of death within 90 days was
assessed in terms of each level of deprivation, age, stage,
comorbidity score and treatment.
Table 2 presents the probability of death within 90 days for male
and female patients in the most and least deprived patients,
according to their age at diagnosis (60, 70 and 80 years), stage at
diagnosis, comorbidity (no recorded comorbidity and the highest
score of 3) and their treatment (major emergency surgery, major
elective surgery or no major surgery). The most deprived patients
were systematically more likely to die within 90 days than the least
deprived patients, irrespective of age, stage, comorbidity and
treatment status. For example, in males aged 70 years, with stage 2
diagnosis, comorbidity score 3 and who underwent a major
emergency treatment, the probability of dying within 90 days was
11.7% (95% confidence interval (CI) 8.3, 16.3%) in the most
deprived compared with 7.9% (95% CI 5.5, 11.2%) in the least
deprived patients. Similarly, among those who underwent a major
elective surgery, the probabilities of death were 3.8% (95% CI 2.7,
5.4%) and 2.5% (95% CI 1.7, 3.6%) in the most and least deprived,
respectively. The probability of death varied by deprivation even
among patients with no recorded comorbidity, regardless of their
treatment. We observed very similar patterns in females.
By contrast, stage-2 patients with no recorded comorbidity
experienced comparable 90-day mortality whether they had no
major surgery or a major emergency surgery (Figure 1, Table 2).
This was the case across all deprivation groups. For example, the
probability of 90-day mortality among the most deprived female
patients aged 70 years was 6.4% (95% CI 4.6, 8.8%) if not receiving
any major surgery and 6.2% (95% CI 4.6, 8.3%) when receiving a
major emergency surgery. These probabilities were much lower
among females receiving a major elective surgery (1.0%, 95% CI
0.7, 1.6% with the same combination of factors). Among men only,
the effect of comorbidity on the probability of 90-day mortality
according to treatment differed: highest in those receiving
Table 1. Patient characteristics – patients diagnosed with colon cancer 2010–2013a in England
Males Females
Total Died within 90 days Total Died within 90 days
N % n %b N % n %b
Deprivation (Income Indices of Multiple Deprivation)
Least deprived (1) 8180 22.3 1018 18.9 7078 21.4 946 17.2
2 8231 22.4 1124 20.9 7241 21.9 1109 20.2
3 7629 20.8 1114 20.7 7048 21.3 1195 21.8
4 7072 19.3 1132 21.1 6649 20.1 1232 22.4
Most deprived (5) 5573 15.2 989 18.4 5068 15.3 1006 18.3
Age (years)
15–40 643 1.8 29 0.5 736 2.2 20 0.4
41–50 1182 3.2 68 1.3 1202 3.6 50 0.9
51–60 3386 9.2 283 5.3 2966 9.0 232 4.2
61–70 9889 27.0 840 15.6 7226 21.8 638 11.6
71–80 12171 33.2 1674 31.1 9785 29.6 1333 24.3
81–99 9414 25.7 2483 46.2 11169 33.8 3215 58.6
Stage
Missing 11186 30.5c 2049 38.1c 10 531 31.8c 2430 44.3c
1 (localised) 3355 13.2d 74 2.2d 2647 11.7d 54 1.8d
2 7084 27.8d 368 11.1d 6571 29.1d 338 11.1d
3 6667 26.1d 388 11.7d 6006 26.6d 401 13.1d
4 (metastatic) 8393 32.9d 2498 75.1d 7329 32.5d 2265 74.1d
Comorbidity score
0 26314 71.7 3380 62.9 24 982 75.5 3600 65.6
1 3780 10.3 697 13.0 3552 10.7 772 14.1
2 3558 9.7 631 11.7 2521 7.6 542 9.9
3þ 3033 8.3 669 12.4 2029 6.1 574 10.5
Treatment
No major treatment 13 390 36.5 4056 75.4 11 811 35.7 4290 78.2
Major emergency treatment 5749 15.7 794 14.8 5962 18.0 868 15.8
Major elective treatment 17 546 47.8 527 9.8 15 311 46.3 330 6.0
Total 36 685 100.0 5377 14.7 33 084 100.0 5488 16.6
a2013 data represent diagnosis between 1 January 2013 and 31 March 2013.
bRepresenting the percentage of patients within each gender who died within 90 days.
cRepresenting the percentage of patients with missing stage information.
dCalculated as a percentage of patients with complete stage information.
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emergency surgery, lowest in those receiving elective surgery, and
intermediate in those with no surgery, regardless of their
deprivation.
We provide graphs illustrating probability of death within 90
days of colon cancer diagnosis against age at diagnosis for each
treatment type in both males and females, at each of the four stages
of diagnosis (Figure 1, Supplementary Figures 2–4). The graphs
contrast probability of death in the most and least deprived groups
in patients with no recorded comorbidities and those with the
maximum comorbidity score of 3. The general pattern was that
more deprived patients were associated with higher 90-day
mortality, regardless of the combination of other prognostic
factors. Figure 1 presents these probabilities for stage-2 patients.
Average predicted probabilities by deprivation. In both males
and females, the average predicted probabilities of death within 90
days of diagnosis identified a clear gradient across the observed
deprivation groups, highest among the most deprived patients and
lowest among the least deprived patients (Table 3, second and
fourth columns). The existence of a difference in the average
predicted probability of death between the most deprived and least
deprived patient groups can be termed a ‘deprivation gap’. The
largest deprivation gap was in females, with 6.5% fewer deaths
predicted within 90 days for the least deprived group compared
with the most deprived (least deprived: 13.4%, 95% CI 12.7, 14.0%;
and most deprived: 19.9%, 95% CI 19.0, 20.7%). In males, this gap
was 5.3% (least deprived: 12.4%, 95% CI 11.8, 13.1%; and most
deprived: 17.7%, 95% CI 16.9, 18.6%).
To explore the deprivation gap further, the probability of death
was recalculated for each of the deprivation groups by predicting
each group’s probability of death as if it were the least deprived
group, while all other prognostic factors remained as observed
(Table 3, third and fifth columns). The results showed a shrinkage
in the difference in probability of death between the most and least
deprived groups, the difference became 1.7% and 1.3% in females
and males, respectively. As expected, we observed the largest
reduction in probability of death in the most deprived group: in
females the reduction was 4.8% and in males the reduction was 4%.
In the additional analysis, when stage, treatment or both stage
and treatment in combination were excluded from the final model
and when the average predicted probability of death was calculated
as if patients belonged to the least deprived group, there was a
further reduction in the mortality difference between the most and
least deprived patients from the one seen in the full analysis model
(Supplementary Table 4). When stage alone was excluded from the
model, the difference in probability of death between the most and
least deprived patients reduced by approximately 30% (absolute
difference of 0.9% compared with 1.3% with the final full model in
males and 1.2% compared with 1.7% in females). For treatment
alone, this percentage was 25% (absolute difference of 1%
compared with 1.3% in males, and 1.3% compared with 1.7% in
females). This suggested that, after accounting for the effect of
deprivation, stage (or treatment) contributed to approximately
one-third (or a quarter) of the remaining difference. When both
stage and treatment were removed from the model, the remaining
difference was close to 0%, indicating that in combination stage
and treatment appear to contribute to most of the remaining
difference in 90-day mortality once the effect of deprivation has
been accounted for.
DISCUSSION
We found a very wide overall range of short-term mortality
probabilities: for example, among female patients aged 60 years,
those diagnosed with early stage colon cancer and who underwent
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Figure 1. Probability (%) of death within 90 days of stage 2 colon cancer diagnosis according to age at diagnosis, among patients with
(i) comorbidity score of 0 or 3 and (ii) from the least or the most deprived group.
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a major elective surgery had a 90-day mortality probability near
0%, compared with a probability between 25% and 55%
(depending on their deprivation group and comorbidity) for those
with a stage-4 diagnosis who did not receive a major surgery.
Deprivation differences in 90-day mortality were seen despite
adjusting for major prognostic factors.
In our patient population, when calculating the average
predicted probability of death within 90 days by deprivation
group, and assuming that patients belong to the least deprived
group, the differences between the probability of death in the least
deprived group and the other deprivation groups became smaller.
It translated to a total of 209 fewer deaths within 90 days of
diagnosis per year in females and 168 fewer deaths per year in
males (about 4% of the number of deaths observed in deprivation
groups 2–5). Furthermore, when considering only the most
deprived group of patients, it equated to approximately 74 and
Table 2. Conditional probabilities of death within 90 days of colon cancer diagnosis
Male Female
Age at diagnosis, years Age at diagnosis, years
60 70 80 60 70 80
Comorbidity
score
Deprivation
group
PoD (%)
(95% CI)
PoD (%)
(95% CI)
PoD (%)
(95% CI)
PoD (%)
(95% CI)
PoD (%)
(95% CI)
PoD (%)
(95% CI)
Stage 1
No major treatment 0 Least 0.2 (0.1; 0.6) 0.7 (0.4; 1.3) 1.9 (1.2; 2.9) 1.4 (0.8; 2.3) 3.8 (2.7; 5.4) 8.0 (6.2; 10.2)
Most 0.4 (0.1; 1.0) 1.1 (0.7; 2.0) 2.9 (1.8; 4.5) 2.3 (1.4; 3.9) 6.4 (4.6; 8.8) 12.9 (10.1; 16.2)
3 Least 0.5 (0.2; 1.3) 0.9 (0.5; 1.6) 1.9 (1.2; 3.0) 2.8 (1.5; 5.5) 7.0 (4.7; 10.3) 11.3 (8.5; 14.9)
Most 0.7 (0.3; 2.0) 1.4 (0.8; 2.4) 2.9 (1.8; 4.6) 4.8 (2.5; 9.0) 11.4 (7.8; 16.4) 17.9 (13.8; 22.9)
Major emergency treatment 0 Least 0.3 (0.1; 1.4) 1.2 (0.4; 3.8) 3.6 (1.2; 10.4) 1.2 (0.7; 2.1) 3.7 (2.7; 5.0) 8.1 (6.5; 10.0)
Most 0.5 (0.1; 2.2) 1.8 (0.6; 5.8) 5.4 (1.8; 15.2) 2.1 (1.3; 3.5) 6.2 (4.6; 8.3) 13.1 (10.7; 16.0)
3 Least 1.1 (0.3; 4.7) 2.4 (0.7; 7.6) 5.9 (1.9; 16.6) 2.6 (1.4; 4.9) 6.8 (4.7; 9.7) 11.6 (9.0; 14.8)
Most 1.7 (0.4; 7.1) 3.6 (1.1; 11.3) 8.9 (3.0; 23.7) 4.3 (2.3; 8.0) 11.1 (7.8; 15.4) 18.3 (14.5; 22.8)
Major elective treatment 0 Least 0.2 (0.1; 0.5) 0.5 (0.3; 0.8) 1.5 (1.0; 2.3) 0.1 (0.1; 0.3) 0.5 (0.4; 0.8) 1.4 (1.0; 1.8)
Most 0.3 (0.1; 0.7) 0.8 (0.5; 1.3) 2.4 (1.6; 3.5) 0.2 (0.1; 0.4) 0.9 (0.6; 1.3) 2.3 (1.8; 3.0)
3 Least 0.6 (0.2; 1.8) 1.1 (0.6; 1.9) 2.9 (1.8; 4.5) 0.3 (0.1; 0.6) 1.0 (0.7; 1.6) 2.0 (1.5; 2.7)
Most 1.0 (0.3; 2.7) 1.7 (1.0; 3.0) 4.4 (2.8; 6.7) 0.5 (0.2; 1.0) 1.7 (1.1; 2.6) 3.4 (2.5; 4.6)
Stage 2
No major treatment 0 Least 1.2 (0.7; 1.9) 3.8 (2.8; 5.1) 7.1 (5.5; 9.3) 1.4 (0.8; 2.3) 3.8 (2.7; 5.4) 8.0 (6.2; 10.2)
Most 1.9 (1.2; 3.0) 5.7 (4.2; 7.7) 10.7 (8.2; 13.8) 2.3 (1.4; 3.9) 6.4 (4.6; 8.8) 12.9 (10.1; 16.2)
3 Least 2.3 (1.3; 4.1) 4.5 (3.2; 6.4) 7.2 (5.4; 9.7) 2.8 (1.5; 5.5) 7.0 (4.7; 10.3) 11.3 (8.5; 14.9)
Most 3.6 (2.1; 6.1) 6.8 (4.9; 9.5) 10.8 (8.1; 14.2) 4.8 (2.5; 9.0) 11.4 (7.8; 16.4) 17.9 (13.8; 22.9)
Major emergency treatment 0 Least 1.2 (0.7; 1.9) 4.1 (3.1; 5.3) 9.1 (7.3; 11.2) 1.2 (0.7; 2.1) 3.7 (2.7; 5.0) 8.1 (6.5; 10.0)
Most 1.8 (1.2; 2.9) 6.2 (4.7; 8.0) 13.4 (10.9; 16.4) 2.1 (1.3; 3.5) 6.2 (4.6; 8.3) 13.1 (10.7; 16.0)
3 Least 3.8 (2.1; 6.7) 7.9 (5.5; 11.2) 14.5 (10.8; 19.1) 2.6 (1.4; 4.9) 6.8 (4.7; 9.7) 11.6 (9.0; 14.8)
Most 5.8 (3.3; 10.0) 11.7 (8.3; 16.3) 20.8 (15.9; 26.8) 4.3 (2.3; 8.0) 11.1 (7.8; 15.4) 18.3 (14.5; 22.8)
Major elective treatment 0 Least 0.4 (0.2; 0.6) 1.1 (0.9; 1.4) 2.6 (2.1; 3.2) 0.1 (0.1; 0.3) 0.5 (0.4; 0.8) 1.4 (1.0; 1.8)
Most 0.6 (0.4; 0.9) 1.7 (1.3; 2.2) 4.0 (3.2; 5.0) 0.2 (0.1; 0.4) 0.9 (0.6; 1.3) 2.3 (1.8; 3.0)
3 Least 1.4 (0.8; 2.4) 2.5 (1.7; 3.6) 4.9 (3.6; 6.6) 0.3 (0.1; 0.6) 1.0 (0.7; 1.6) 2.0 (1.5; 2.7)
Most 2.1 (1.2; 3.7) 3.8 (2.7; 5.4) 7.4 (5.5; 9.9) 0.5 (0.2; 1.0) 1.7 (1.1; 2.6) 3.4 (2.5; 4.6)
Stage 3
No major treatment 0 Least 3.2 (2.3; 4.5) 5.8 (4.6; 7.3) 9.8 (7.9; 12.1) 2.6 (1.7; 3.8) 4.7 (3.5; 6.2) 7.3 (5.8; 9.3)
Most 4.9 (3.5; 6.9) 8.8 (6.9; 11.0) 14.5 (11.8; 17.7) 4.3 (2.9; 6.4) 7.7 (5.8; 10.2) 11.9 (9.4; 14.9)
3 Least 6.1 (3.9; 9.4) 6.9 (5.2; 9.2) 9.9 (7.7; 12.7) 5.2 (3.0; 9.0) 8.5 (6.0; 11.9) 10.5 (8.0; 13.5)
Most 9.2 (6.0; 13.8) 10.4 (7.9; 13.5) 14.6 (11.5; 18.4) 8.6 (5.1; 14.4) 13.7 (9.9; 18.7) 16.6 (13.0; 21.1)
Major emergency treatment 0 Least 2.0 (1.4; 2.9) 4.0 (3.1; 5.1) 8.1 (6.5; 10.1) 3.0 (2.1; 4.2) 5.7 (4.6; 7.2) 9.4 (7.8; 11.4)
Most 3.1 (2.2; 4.4) 6.1 (4.8; 7.6) 12.0 (9.7; 14.8) 5.0 (3.5; 7.0) 9.4 (7.5; 11.7) 15.1 (12.5; 18.0)
3 Least 6.3 (3.9; 10.1) 7.7 (5.5; 10.7) 13.0 (9.7; 17.3) 6.1 (3.6; 10.0) 10.3 (7.6; 13.9) 13.3 (10.5; 16.7)
Most 9.4 (5.9; 14.8) 11.5 (8.3; 15.7) 18.8 (14.3; 24.4) 9.9 (6.0; 16.0) 16.4 (12.3; 21.5) 20.8 (16.8; 25.4)
Major elective treatment 0 Least 0.5 (0.4; 0.8) 0.9 (0.7; 1.2) 2.0 (1.5; 2.6) 0.3 (0.2; 0.6) 0.9 (0.6; 1.2) 1.6 (1.3; 2.2)
Most 0.8 (0.6; 1.2) 1.4 (1.1; 1.9) 3.1 (2.4; 4.0) 0.6 (0.4; 0.9) 1.5 (1.1; 2.0) 2.8 (2.1; 3.7)
3 Least 2.0 (1.2; 3.3) 2.1 (1.5; 3.0) 3.7 (2.6; 5.2) 0.7 (0.4; 1.4) 1.6 (1.1; 2.4) 2.4 (1.8; 3.3)
Most 3.0 (1.8; 5.0) 3.2 (2.2; 4.6) 5.7 (4.1; 7.9) 1.2 (0.6; 2.3) 2.8 (1.9; 4.0) 4.1 (3.0; 5.5)
Stage 4
No major treatment 0 Least 24.9 (22.7; 27.2) 33.2 (31.0; 35.4) 46.0 (43.4; 48.7) 24.4 (22.0; 27.0) 34.2 (31.8; 36.7) 49.1 (46.3; 51.9)
Most 33.9 (31.2; 36.8) 43.5 (40.9; 46.1) 57.0 (54.2; 59.7) 35.6 (32.4; 38.9) 47.1 (44.2; 49.9) 62.3 (59.4; 65.0)
3 Least 39.4 (31.6; 47.7) 37.5 (32.6; 42.6) 46.3 (41.8; 50.9) 40.5 (30.3; 51.6) 49.5 (42.9; 56.2) 58.8 (53.8; 63.6)
Most 50.2 (41.8; 58.6) 48.2 (42.9; 53.4) 57.3 (52.7; 61.7) 53.8 (42.7; 64.5) 62.7 (56.3; 68.7) 70.9 (66.6; 74.9)
Major emergency treatment 0 Least 11.9 (9.8; 14.4) 18.1 (15.9; 20.6) 31.4 (27.9; 35.2) 11.1 (9.0; 13.6) 17.6 (15.3; 20.1) 29.6 (26.2; 33.2)
Most 17.3 (14.5; 20.6) 25.6 (22.7; 28.7) 41.6 (37.3; 45.9) 17.5 (14.4; 21.2) 26.7 (23.5; 30.2) 41.8 (37.6; 46.1)
3 Least 30.7 (22.1; 40.9) 30.9 (24.4; 38.2) 43.7 (36.3; 51.4) 20.8 (13.9; 29.9) 28.7 (23.0; 35.2) 38.3 (32.8; 44.1)
Most 40.8 (30.6; 51.8) 41.0 (33.4; 48.9) 54.6 (46.9; 62.2) 31.0 (21.7; 42.1) 40.8 (33.9; 48.0) 51.5 (45.5; 57.5)
Major elective treatment 0 Least 3.8 (2.9; 5.0) 5.3 (4.4; 6.4) 10.4 (8.6; 12.6) 1.9 (1.3; 2.8) 4.1 (3.2; 5.2) 8.5 (6.9; 10.5)
Most 5.8 (4.4; 7.5) 7.9 (6.6; 9.5) 15.3 (12.7; 18.3) 3.2 (2.2; 4.6) 6.8 (5.3; 8.5) 13.7 (11.2; 16.7)
3 Least 12.7 (8.3; 19.0) 11.2 (8.2; 15.1) 18.1 (13.8; 23.4) 3.9 (2.2; 6.7) 7.4 (5.4; 10.2) 12.1 (9.4; 15.5)
Most 18.5 (12.4; 26.6) 16.4 (12.3; 21.5) 25.6 (19.9; 32.2) 6.5 (3.7; 11.0) 12.1 (8.8; 16.2) 19.0 (15.0; 23.8)
Abbreviations: CI¼ confidence interval; PoD¼probability of death.
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69 fewer deaths in females and males, respectively. These results
suggested that the differential distribution of the prognostic factors
in deprivation groups may account for some of the outcome
differences observed.
In the additional analysis, when we explored the role stage and
treatment may be having in 90-day mortality differences between
the most and least deprived patients, we found that stage and
treatment appeared to contribute towards almost all of the
remaining difference between the most and least deprived patient
groups. When the average predicted probability of death was
calculated assuming all patients were in the least deprived group
and after removing both stage and treatment from the model, the
average predicted probabilities were almost the same between the
most and least deprived patient groups.
Differential access of treatment by deprivation may explain
some of the inequalities in mortality. The percentage of colon
cancer cases diagnosed during an emergency admission was as
high as 31.4% in England for diagnoses made between 2006 and
2010 (Abel et al, 2015). In Scotland, the most deprived patients
were more likely to present as an emergency and undergo palliative
surgery (Oliphant et al, 2013). The same study also found higher
postoperative mortality among more deprived colorectal patients,
after adjusting for comorbidity and stage. These findings are in line
with ours, where the socio-economic differences in 90-day
mortality were evident in both nonoperative and postoperative
colon cancer patients. Comorbidity and stage provide some
contribution towards differences in short-term cancer mortality,
but the socio-economic inequalities in 90-day mortality probability
persisted even within any given treatment category, after control-
ling for stage and comorbidity. In the context of randomised
clinical trials, where stage, comorbidity and also treatment are well
controlled, we did not find evidence of a deprivation gap in 1-year
colorectal cancer survival (Nur et al, 2008).
In a broader context, other work discussed differences in the
quality of postoperative care and availability of beds in high
dependence and intensive care units in the institution where
treatment is received as potential factors influencing short-term
postoperative mortality (Morris et al, 2011). This is especially
pertinent in the presence of a high prevalence of postoperative
complications. Previous research in Australia found that patients
from higher socio-economic areas had a lower risk of developing
postoperative complications (Beckmann et al, 2016), reinforcing
the need for adequate postoperative care facilities in the most
deprived areas. Comparing postoperative care resourcing between
institutions in more and lesser deprived areas could provide some
explanation behind socio-economic differences in 90-day colon
cancer mortality and should be examined in more detail. Our study
included surgical treatment received up to 90 days after diagnosis
but did not account for the time to surgical treatment. Other
research has shown more deprived patients were more likely to
receive late treatment, that is, later than a month since diagnosis
(Lejeune et al, 2010).
The results of this study provided some insight into an existing
dynamic between treatment, comorbidity and short-term mortal-
ity. This relationship has some complexity, as comorbidity affects
survival and influences cancer management (Faivre et al, 2007).
This complexity is more pronounced in the elderly: the frequency
of comorbidity is often higher in the elderly (Colorectal Cancer
Collaborative Group, 2000), they tend to have more advanced
disease stage (Dekker et al, 2011), and postoperative mortality
increases with age (Morris et al, 2011). Additionally, patients
undergoing emergency major surgery had a higher 90-day
probability of death than patients who had received elective major
treatment. This concurs with previous research indicating
emergency surgery in comorbid patients to be a risk factor for
short-term mortality in postoperative colon cancer patients
(Gooiker et al, 2012).
Some challenges were faced when conducting analyses for this
study, in particular owing to the use of population-based data. We
employed a robust imputation strategy to mitigate the disadvan-
tage of having missing information on stage (Bartlett et al, 2015).
This approach allowed us to select the most parsimonious model as
the final model to predict probability of death within 90 days, while
taking proper account of the missing data. The overall probability
of 90-day mortality was estimated as 14.7% (95% CI 14.4, 15.0%)
for males and 16.6% (95% CI 16.3, 16.9%) for females. These
predictions closely align with the observed proportion of deaths
occurring within 90 days in our study population, confirming the
goodness of fit of the analysis model on the observed data.
Information on treatment received by patients in our study was
obtained using records from public hospitals. Some patients in our
study may have received treatment in private facilities, which is not
captured in our study. However, the proportion of cancer patients
receiving surgical treatment outside the National Health Service
has historically been small (Lawrence, 2013).
Our method for deriving patient comorbidity information
was dependent on patients visiting the hospital and being
diagnosed with the comorbidity in the time period of interest.
We acknowledge the possibility that some comorbid adults may
not have attended hospital nor had a comorbidity diagnosis
recorded in this time, and therefore their comorbidity score
would be 0. When available, including nonsurgical treatment
in the analysis may provide additional insight into disparities
in 90-day mortality between colon cancer patient groups,
although surgery remains the primary curative treatment for
colon cancer.
In conclusion, this study gives a full picture of 90-day
probability of death according to the main prognostic factors
and highlights persistent socio-economic inequalities in short-term
mortality, even after accounting for the main prognostic factors,
Table 3. Average predicted probability of death within 90 days of colon cancer diagnosis: by deprivation
Males Females
Deprivation
group
Average
predicted
probabilitya
(95% CI)
Average predicted probability, adjusted
as if patients belonged to the deprivation
group 1b (95% CI)
Average
predicted
probabilitya
(95% CI)
Average predicted probability, adjusted
as if patients belonged to the deprivation
group 1b (95% CI)
Least deprived (1) 12.4 (11.8; 13.1) 12.4 (11.8; 13.1) 13.4 (12.7; 14.0) 13.4 (12.7; 14.0)
2 13.7 (13.0; 14.3) 12.9 (12.2; 13.5) 15.3 (14.7; 16.0) 14.1 (13.4; 14.8)
3 14.6 (13.9; 15.3) 13.3 (12.6; 14.0) 17.0 (16.3; 17.6) 14.8 (14.0; 15.5)
4 16.0 (15.3; 16.7) 13.6 (13.0; 14.3) 18.5 (17.8; 19.3) 15.5 (14.7; 16.2)
Most deprived (5) 17.7 (16.9; 18.6) 13.7 (13.0; 14.3) 19.9 (19.0; 20.7) 15.1 (14.4; 15.9)
Abbreviation: CI¼ confidence interval.
aProbability predicted for each deprivation group based on the observed value of the deprivation group, with the distribution of all prognostic factors remaining as observed.
bProbability predicted for each deprivation group adjusted to assume patients in each group belong to the least deprived group (group 1), with the distribution of all prognostic factors
remaining as observed.
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including prediagnosis comorbidities that could be derived from
hospital attendance records and cancer registry data. Indeed, these
socio-economic differences in 90-day mortality were especially
apparent in the older patients, as probability of 90-day mortality
increased with age. The provision of treatment involves considera-
tion as to whether patients can withstand the trauma of surgery,
particularly where patients have comorbid conditions. This is
especially true in older patients more vulnerable to the aftermath of
surgery. The planning of cancer treatment and care would need to
focus decisions to treat patients on patient performance status and
comorbidities, rather than their chronological age (Lawler et al,
2014). Socio-economic inequalities in 90-day mortality being
found even among non-vulnerable patients suggest that resources
for optimal treatment planning and postoperative care facilities
may not be equally accessible to all patient deprivation groups.
This study has identified a need to focus on understanding what is
driving the effect of deprivation on 90-day mortality, including
differences in health-care-seeking behaviours. Based on the
findings of this population-based study, beneficial health policy
initiatives could include targeted screening programmes to
facilitate earlier-stage diagnosis in vulnerable patient groups,
improved preoperative planning, including evaluation of comorbid
patients, and more stringent postoperative monitoring of the
patients.
ACKNOWLEDGEMENTS
This research was supported by Cancer Research UK grant number
C7923/A18525. The findings and conclusions in this report are
those of the authors and do not necessarily represent the views of
Cancer Research UK.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ETHICAL APPROVAL
Statutory approval updated 26 May 2017 (PIAG 1-05(c)/2007;
ECC 1-05(a)/2010); ethical approval updated 6 April 2017 (REC
13/LO/0610).
REFERENCES
Aarts MJ, Lemmens VE, Louwman MW, Kunst AE, Coebergh JW (2010)
Socioeconomic status and changing inequalities in colorectal cancer?
A review of the associations with risk, treatment and outcome. Eur J
Cancer 46: 2681–2695.
Abel GA, Shelton J, Johnson S, Elliss-Brookes L, Lyratzopoulos G (2015)
Cancer-specific variation in emergency presentation by sex, age and
deprivation across 27 common and rarer cancers. Br J Cancer
112(Suppl 1): S129–S136.
Agresti A (2013) Categorical Data Analysis. Wiley Press: Hoboken, NJ, USA.
Antunes L, Mendonc¸a D, Bento MJ, Rachet B (2016) No inequalities in
survival from colorectal cancer by education and socioeconomic
deprivation—a population-based study in the North Region of Portugal,
2000-2002. BMC Cancer 16: 1–12.
Bartlett JW, Morris TP (2015) Multiple imputation of covariates by substantive-
model compatible fully conditional specification. Stata J 15: 437–456.
Bartlett JW, Seaman SR, White IR, Carpenter JR (2015) Multiple imputation
of covariates by fully conditional specification: Accommodating the
substantive model. Stat Methods Med Res 24: 462–487.
Beckmann K, Moore J, Wattchow D, Young G, Roder D (2016) Short-term
outcomes after surgical resection for colorectal cancer in South Australia.
J Eval Clin Pract 23: 316–324.
Benitez-Majano S, Fowler H, Maringe C, Di Girolamo C, Rachet B (2016)
Deriving stage at diagnosis from multiple population-based sources:
colorectal and lung cancer in England. Br J Cancer 115: 391–400.
Carpenter J, Kenward M (2013) Multiple Imputation and its Application.
Wiley Press: Chichester, UK.
Cavalli-Bjorkman N, Lambe M, Eaker S, Sandin F, Glimelius B (2011)
Differences according to educational level in the management and survival
of colorectal cancer in Sweden. Eur J Cancer 47: 1398–1406.
Charlson ME, Pompei P, Ales KL, Mackenzie CR (1987) A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. J Chron Dis 40: 373–383.
Colorectal Cancer Collaborative Group (2000) Surgery for colorectal cancer in
elderly patients: a systematic review. Colorectal Cancer Collaborative
Group. Lancet 356: 968–974.
Dejardin O, Rachet B, Morris E, Bouvier V, Jooste V, Haynes R, Coombes EG,
Forman D, Jones AP, Bouvier AM, Launoy G (2013) Management of
colorectal cancer explains differences in 1-year relative survival between
France and England for patients diagnosed 1997-2004. Br J Cancer 108:
775–783.
Dekker JW, Van Den Broek CB, Bastiaannet E, Van De Geest LG, Tollenaar RA,
Liefers GJ (2011) Importance of the first postoperative year in the prognosis
of elderly colorectal cancer patients. Ann. Surg. Oncol 18: 1533–1539.
Department for Communities and Local Government (2011) The English
Indices of Deprivation 2010, London.
Ellis L, Coleman MP, Rachet B (2012) How many deaths would be avoidable
if socioeconomic inequalities in cancer survival in England were
eliminated? A national population-based study, 1996-2006. Eur J Cancer
48: 270–278.
Exarchakou A, Rachet B, Nash E, Bannister N, Coleman MP, Rowlands S
(2015) Cancer Survival in England: Adults Diagnosed in 2009 to 2013,
Followed up to 2014. Office for National Statistics: Newport, Wales.
Faivre J, Lemmens VE, Quipourt V, Bouvier AM (2007) Management and
survival of colorectal cancer in the elderly in population-based studies. Eur
J Cancer 43: 2279–2284.
Falcaro M, Nur U, Rachet B, Carpenter JR (2015) Estimating excess hazard
ratios and net survival when covariate data are missing: strategies for
multiple imputation. Epidemiology 26: 421–428.
Gatta G, Faivre J, Capocaccia R, Ponce De Leo´n A, Eurocare Working Group
(1998) Survival of colorectal cancer patients in Europe during the period
1978-1989. Eur J Cancer 34: 2176–2183.
Gooiker GA, Dekker JW, Bastiaannet E, Van Der Geest LG, Merkus JW,
Van De Velde CJ, Tollenaar RA, Liefers GJ (2012) Risk factors for excess
mortality in the first year after curative surgery for colorectal cancer. Ann
Surg Oncol 19: 2428–2434.
Health and Social Care Information Centre (2013) Hospital Episode Statistics
[Online]. Available at: http://www.hscic.gov.uk/hes (accessed 18
November 2013).
Health and Social Care Information Centre (2017) OPCS-4 Classification
[Online]. Available at: https://digital.nhs.uk/article/1117/Clinical-
Classifications (last accessed 17 August 2017).
Health and Social Care Information Centre (2014a) National Bowel Cancer
Audit.
Health and Social Care Information Centre (2014b) National Bowel Cancer
Audit Report 2014.
Ito Y, Nakaya T, Nakayama T, Miyashiro I, Ioka A, Tsukuma H, Rachet B
(2014) Socioeconomic inequalities in cancer survival: a population-based
study of adult patients diagnosed in Osaka, Japan, during the period
1993-2004. Acta Oncol 53: 1423–1433.
Lawler M, Selby P, Aapro M, Duffy S (2014) Ageism in cancer care. BMJ 348:
g1614.
Lawrence G (2013) Further analysis of ICBP treatment data (version 1.2).
Lejeune C, Sassi F, Ellis L, Godward S, Mak V, Day M, Rachet B (2010)
Socioeconomic disparities in access to treatment and their impact on
colorectal cancer survival. Int J Epidemiol 39: 710–717.
Little R, Rubin D (1987) Statistical Analysis with Missing Data. John Wiley &
Sons: Newport, England.
Maringe C, Fowler H, Rachet B, Luque-Ferna´ndez MA (2017) Reproducibility,
reliability and validity of population-based administrative health data for
the assessment of cancer non-related comorbidities. PLoS One 12(3):
e0172814.
BRITISH JOURNAL OF CANCER Persistent inequalities in 90-day mortality
8 www.bjcancer.com |DOI:10.1038/bjc.2017.295
Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP (2008) Survival from
cancer of the colon in England and Wales up to 2001. Br J Cancer
99(Suppl 1): 26–29.
Møller H, Sandin F, Robinson D, Bray F, Klint S, Linklater KM, Lambert PC,
Pahlman L, Holmberg L, Morris E (2012) Colorectal cancer survival in
socioeconomic groups in England: variation is mainly in the short term
after diagnosis. Eur J Cancer 48: 46–53.
Morris EJ, Taylor EF, Thomas JD, Quirke P, Finan PJ, Coleman MP, Rachet B,
Forman D (2011) Thirty-day postoperative mortality after colorectal
cancer surgery in England. Gut 60: 806–813.
Muller C, MacLehose R (2014) Estimating predicted probabilities from logistic
regression: different methods correspond to different target populations.
Int J Epidemiol 43: 962–970.
National Cancer Intelligence Network (2013) Site Specific Clinical Reference
Groups (SSCRGs) [Online]. Available at: http://www.ncin.org.uk/
cancer_type_and_topic_specific_work/cancer_type_specific_work/sscrgs
(accessed 14 October 2014).
Nur U, Rachet B, Parmar MKB, Sydes M, Cooper N, Lepage C, Northover JMA,
James R, Coleman MP, Collaborators, A (2008) No socioeconomic
inequalities in colorectal cancer survival within a randomised clinical trial.
Br J Cancer 99: 1923–1928.
Office for National Statistics (2014) Cancer Registration Statistics, England:
First Release, 2014. Office for National Statistics: Newport, England.
Oliphant R, Nicholson G, Horgan P, Molloy R, Mcmillan D, Morrison D
(2013) Deprivation and colorectal cancer surgery: longer-term survival
inequalities are due to differential postoperative mortality between
socioeconomic groups. Ann Surg Oncol 20.
Rachet B, Ellis L, Maringe C, Nur U, Chu T, Quaresma M, Shah A, Walters S,
Woods LM, Forman D, Coleman MP (2010) Socioeconomic inequalities
in cancer survival in England after the NHS Cancer Plan. Br J Cancer 103:
446–453.
Shack LG (2009) What factors influence socio-economic inequalities in
colorectal cancer survival?. PhD ThesisLondon School of Hygiene and
Tropical Medicine: London, UK.
StataCorp (2015) STATA Statistical Software. 14 edn. (Stata Corporation:
College Station, TX, USA.
Wrigley H, Roderick P, George S, Smith J, Mullee M, Goddard J (2002)
Inequalities in survival from colorectal cancer: a comparison of
the impact of deprivation, treatment and host factors on
observed and cause specific survival. J Epidemiol Community Health
56: 1–8.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a copy
of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) named above 2017
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Persistent inequalities in 90-day mortality BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.295 9
